Keywords
Premature Infants
Pediatrics
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the characteristics of Bronchopulmonary Dysplasia (BPD). Bibliographic review: BPD is potentially one of the most devastating conditions in premature babies, with long-lasting consequences involving adverse effects on lung function and neurological development. BPD is defined as oxygen requirement for ≥ 28 days from birth to 36 weeks of postmenstrual age. It is the most common complication of premature birth, occurring in 43% of babies born at 28 weeks of gestation or less, and is characterized by arrested lung growth, alveolar simplification, impaired blood vessel development, and abnormal lung function. The incidence of BPD increases with decreasing gestational age (GA) and birth weight. Final considerations: BPD consists of a severe cardiorespiratory morbidity that affects infants born prematurely and/or with very low birth weight, being classified as mild, moderate and severe depending on the infant's need for supplemental oxygen. Its management is carried out through adequate nutrition and moderate fluid restriction, in addition to the administration of diuretics such as furosemide and corticoids such as hydrocortidosone.
References
ANDERSON C, HILLMAN NH. Bronchopulmonary Dysplasia: When the Very Preterm Baby Comes Home. Mo Med. 2019; 116(2): 117-122.
AOYAMA BC, et al. Mortality in Outpatients with Bronchopulmonary Dysplasia. J Pediatr. 2022; 241: 48-53.
BOUCHERAT O, et al. Revisiting the Role for HIF Stabilizers in Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2020; 202(8): 1075-1077.
DOYLE LW. Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia. Neonatology. 2021; 118(2): 244-251.
DUIJTS L, et al. European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia. Eur Respir J. 2020; 55(1): 1900788.
GILFILLAN M, BHANDARI V. Moving bronchopulmonary dysplasia research from the bedside to the bench. Am J Physiol Lung Cell Mol Physiol. 2022; 322(6): 804-821.
GIUSTO K, et al. Hyperoxia-induced bronchopulmonary dysplasia: better models for better therapies. Dis Model Mech. 2021; 14(2): dmm047753.
HANSMANN G, et al. Pulmonary hypertension in bronchopulmonary dysplasia. Pediatr Res. 2021; 89(3): 446-455.
HIGANO NS, et al. Modern pulmonary imaging of bronchopulmonary dysplasia. J Perinatol. 2021; 41(4): 707-717.
HIGANO NS, et al. Bronchopulmonary dysplasia from chest radiographs to magnetic resonance imaging and computed tomography: adding value. Pediatr Radiol. 2022; 52(4): 643-660.
HIGGINS RD, et al. Bronchopulmonary Dysplasia: Executive Summary of a Workshop. J Pediatr. 2018; 197: 300-308.
HOMAN TD, NAYYAK RP. Short- and Long-Term Complications of Bronchopulmonary Dysplasia. Respir Care. 2021; 66(10): 1618-1629.
HTUN ZT, et al. Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia. J Perinatol. 2021; 41(8): 1783-1796.
HWANG JS, REHAN VK. Recent Advances in Bronchopulmonary Dysplasia: Pathophysiology, Prevention, and Treatment. Lung. 2018; 196(2): 129-138.
JENSEN EA, et al. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med. 2019; 200(6): 751-759.
MOSCHINO L, et al. Lung growth and pulmonary function after prematurity and bronchopulmonary dysplasia. Pediatr Pulmonol. 2021; 56(11): 3499-3508.
OMAR SA, et al. Stem-Cell Therapy for Bronchopulmonary Dysplasia (BPD) in Newborns. Cells. 2022; 11(8): 1275.
PRINCIPI N, et al. Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies. J Transl Med. 2018; 16(1): 36.
SAHNI M, BHANDARI V. Recent advances in understanding and management of bronchopulmonary dysplasia. F1000Res. 2020; 9: PMC7361502.
SALIMI U, et al. Postnatal Sepsis and Bronchopulmonary Dysplasia in Premature Infants: Mechanistic Insights into "New BPD". Am J Respir Cell Mol Biol. 2022; 66(2): 137-145.
SAVANI RC. Modulators of inflammation in Bronchopulmonary Dysplasia. Semin Perinatol. 2018; 42(7): 459-470.
THÉBAUD B, et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019; 5(1): 78.
WANG SH, TSAO PN. Phenotypes of Bronchopulmonary Dysplasia. Int J Mol Sci. 2020; 21(17): 6112.
WATTERBERG KL, et al. Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia. N Engl J Med. 2022; 386(12): 1121-1131.
ZIMMERMANN LJI, et al. Tackling bronchopulmonary dysplasia to improve preterm health: a call for family-centered care at World Prematurity Day 2020. Am J Physiol Lung Cell Mol Physiol. 2020; 319(5): 867-870.